A nosocomial outbreak of infections due to multiply resistant Proteus mirabilis: role of intestinal colonization as a major reservoir

The Journal of Infectious Diseases
A W ChowL B Guze

Abstract

An outbreak of nosocomial infections involving an unusual strain of multiply resistant Proteus mirabilis (phage type 8888) occurred in 15 patients, 14 of whom were in the surgical intensive care unit at that time. No common source of infection was identified, and person-to-person transmission was the most likely mode of spread. Case-control analysis indicated a significantly increased risk infection related to length of hospital stay (P less than 0.005), number of operations (P less than 0.005), proximity to another case (P less than 0.01), number of antibiotics received (P less than 0.02), and use of a respirator (P less than 0.01). Only the number of operations (P less than 0.01) and proximity to another case (P less than 0.05) remained significant risk factors when related parameters were controlled by multivariate analysis. Thirteen of 14 patients prospectively cultured were colonized by the epidemic organism in the intestinal tract, while rectal carriage preceded infection by the same strain in at least four patients. These data suggest that intestinal colonization may have been an important reservoir for this outbreak, and the findings may explain the unduly prolonged course of intrahospital spread as well as the difficul...Continue Reading

Citations

Dec 1, 1992·International Journal of Antimicrobial Agents·G Amaya-TapiaE Rodriguez-Noriega
Nov 1, 1989·Zentralblatt Für Bakteriologie : International Journal of Medical Microbiology·H E Müller
Dec 2, 2000·Microbes and Infection·C CokerH L Mobley
Mar 28, 2012·Antimicrobial Agents and Chemotherapy·Mario TumbarelloTeresa Spanu
Jan 19, 2008·Clinical Microbiology Reviews·S M JacobsenM E Shirtliff
Nov 1, 1983·Gut·H J O'Connor, A T Axon
Oct 27, 2016·Microbial Ecology·Dominika Drzewiecka
Jul 1, 1987·The Journal of Hospital Infection·D A DanceJ A Lowes
Jan 1, 1983·Scandinavian Journal of Infectious Diseases·A Eddeland, H Hedelin
Dec 6, 2012·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·A AdlerUNKNOWN MOSAR WP5 & WP2 study groups
Nov 3, 1979·Lancet
Oct 1, 1990·Clinical Pediatrics·E V Ross
Jun 15, 2018·Clinical Microbiology Reviews·Amy L HamiltonMark Morrison
Mar 13, 2020·Journal of Basic Microbiology·Li JinXiao-Xia Ma
Nov 1, 1982·Infection Control : IC·S A Murray, D R Snydman
Jun 1, 1990·Applied and Environmental Microbiology·S E GeorgeL D Claxton
Mar 1, 1986·Journal of Clinical Microbiology·P M HawkeyR A Simpson
Mar 1, 1986·Journal of Clinical Microbiology·E L LarsonJ J Leyden
Sep 1, 1989·Journal of Clinical Microbiology·N J EhrenkranzL B Moskowitz
Mar 1, 1997·Microbiology and Molecular Biology Reviews : MMBR·A RózalskiK Kotełko
Oct 1, 1984·Disease-a-month : DM·H C Neu

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Bacteriophage: Phage Therapy

Phage therapy uses bacterial viruses (bacteriophages) to treat bacterial infections and is widely being recognized as an alternative to antibiotics. Here is the latest research.